337 related articles for article (PubMed ID: 25787321)
1. [Acute myeloid leukemia].
Döhner K; Paschka P; Döhner H
Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
[TBL] [Abstract][Full Text] [Related]
2. [Acute myeloid leukemia. Genetic diagnostics and molecular therapy].
Schlenk RF; Döhner K; Döhner H
Internist (Berl); 2013 Feb; 54(2):171-8. PubMed ID: 23358744
[TBL] [Abstract][Full Text] [Related]
3. [Acute myeloid Leukemia].
Braess J
Dtsch Med Wochenschr; 2016 Nov; 141(24):1748-1751. PubMed ID: 27835920
[TBL] [Abstract][Full Text] [Related]
4. [Acute myeloid leukemia].
Ohtake S
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2175-9. PubMed ID: 18079616
[TBL] [Abstract][Full Text] [Related]
5. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
DiNardo C; Lachowiez C
Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
[TBL] [Abstract][Full Text] [Related]
6. Pathology Consultation on Gene Mutations in Acute Myeloid Leukemia.
Ziai JM; Siddon AJ;
Am J Clin Pathol; 2015 Oct; 144(4):539-54. PubMed ID: 26386075
[TBL] [Abstract][Full Text] [Related]
7. A concise review on the molecular genetics of acute myeloid leukemia.
Padmakumar D; Chandraprabha VR; Gopinath P; Vimala Devi ART; Anitha GRJ; Sreelatha MM; Padmakumar A; Sreedharan H
Leuk Res; 2021 Dec; 111():106727. PubMed ID: 34700049
[TBL] [Abstract][Full Text] [Related]
8. [What is recommended in the treatment of acute myeloid leukemia?].
Thol F
Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
[TBL] [Abstract][Full Text] [Related]
9. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.
Kadia TM; Ravandi F; Cortes J; Kantarjian H
JAMA Oncol; 2015 Sep; 1(6):820-8. PubMed ID: 26181162
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
11. Frontline treatment of acute myeloid leukemia in adults.
Tamamyan G; Kadia T; Ravandi F; Borthakur G; Cortes J; Jabbour E; Daver N; Ohanian M; Kantarjian H; Konopleva M
Crit Rev Oncol Hematol; 2017 Feb; 110():20-34. PubMed ID: 28109402
[TBL] [Abstract][Full Text] [Related]
12. [Gene mutations in acute myeloid leukemia].
Yamaguchi H
Rinsho Ketsueki; 2016; 57(12):2535-2542. PubMed ID: 28090023
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
14. Molecular markers in acute myeloid leukaemia.
Kühnl A; Grimwade D
Int J Hematol; 2012 Aug; 96(2):153-63. PubMed ID: 22791509
[TBL] [Abstract][Full Text] [Related]
15. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
17. Intermediate-risk acute myeloid leukemia therapy: current and future.
Döhner K; Paschka P
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):34-43. PubMed ID: 25696832
[TBL] [Abstract][Full Text] [Related]
18. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
Guenounou S; Delabesse E; Récher C
Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
[TBL] [Abstract][Full Text] [Related]
20. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
